Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin (2022)

Peer-Reviewed Study · Takashi Ishiguro, Rie H. Ishiguro, Masako Ishiguro, Atsuko Toki, Hiroshi Terunuma · February 3, 2022

Takashi Ishiguro et al., 2022-02-03: Japanese case report of three patients (breast cancer, osteosarcoma, lung adenocarcinoma) given ivermectin 12 mg one to two times weekly within a full or partial combination of dichloroacetate, omeprazole and tamoxifen, with symptom relief and, in one patient, falls in CEA and CA15-3.

Hence, we added a tablet of 12 mg ivermectin per day (on Day 1), which stabilized pleural effusion and induced tumor marker reduction (CEA or carcinoembryonic antigen), which went down from 12.9 to 7.3

Takashi Ishiguro et al., 2022-02-03: Japanese case report of three patients (breast cancer, osteosarcoma, lung adenocarcinoma) given ivermectin 12 mg one to two times weekly within a full or partial combination of dichloroacetate, omeprazole and tamoxifen, with symptom relief and, in one patient, falls in CEA and CA15-3. C3. Study type: case report/series, n=3, Japan (Kamui Medical Co. Ltd, Tokyo; Tama Nanbu Chiiki Hospital; N2 Clinic Yotsuya). No comparator, no control. Doses as reported: Case 1, 69-year-old woman with metastatic breast cancer – DCA 3×333 mg/day, omeprazole 3×40 mg/day, tamoxifen 20 mg/day weekly (Days 1), plus ivermectin 12 mg/day on Day 1; pleural effusion stabilised, CEA 12.9->7.3 and CA15-3 302.3->229.4 over 3 months. Case 2, 54-year-old man with recurrent osteosarcoma – same drugs on Days 1 and 4 plus ivermectin 12 mg on Days 1 and 4; symptoms relieved after one cycle. Case 3, 54-year-old man with lung adenocarcinoma – ivermectin 12 mg weekly then twice weekly; symptoms relieved after the change. Funding: not stated. Disclosures: 'The authors have declared that no competing interests exist' – NOTE the first three authors are affiliated with Kamui Medical Co. Ltd, a company, which the paper does not discuss. Outcomes are symptoms, tumour markers and one imaging change, not RECIST responses; no survival data. Evidence cannot be attributed to ivermectin alone because of the four-drug combination. Also filed as IVD-44 (claims C3, C7).